Compare Aurora Cannabis Inc (ACB) vs NICE Ltd (NICE) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

NICE trades at $97.17, up 0.44% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company shows strong profitability with a 65.79% gross margin and 17.57% net income margin, while recent news highlights AI platform expansions with Sopra Steria and AWS European Sovereign Cloud deployment (Business Wire, 2026-07-01).

The stock presents a compelling value opportunity with a P/E of 11.53 below sector averages, supported by a $124.88 analyst price target implying 28% upside. Risks include projected net income decline to $530M in 2026 and overbought short-term RSI levels. Wall Street sentiment remains positive with 13 buy ratings and no sell recommendations.